Search Orphan Drug Designations and Approvals
-
| Generic Name: | small molecule that selectively and irreversibly inhibits the KRAS p.G12C mutant protein |
|---|---|
| Date Designated: | 07/22/2025 |
| Orphan Designation: | treatment of colorectal cancer (CRC) harboring KRAS p.G12C mutant protein |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
D3 Bio (Wuxi) Co., Ltd 1101, Tower 1, No.6, Lane 38, Yuanshan Road Pudong Shanghai 200120 China The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







